<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027764</url>
  </required_header>
  <id_info>
    <org_study_id>TSA-01</org_study_id>
    <nct_id>NCT04027764</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer</brief_title>
  <official_title>Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center， Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dai, Guanghai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of
      treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and
      Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment
      continually until disease progression or intolerable toxicity or Patients withdrawal of
      consent.and target sample is 30+ patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Toripalimab: 240 mg , once every 2-3 weeks; S1: 80-120mg, bid; oral, day1-14; Albumin
      paclitaxel: 120mg/m2 , administered on the first day and the eighth day of each cycle; 21
      days for a treatment cycle
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease response rate</measure>
    <time_frame>1 year</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Toripalimab Combined With S1 and Albumin Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab Combined With S1 and Albumin Paclitaxel</intervention_name>
    <description>Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \8</description>
    <arm_group_label>Toripalimab Combined With S1 and Albumin Paclitaxel</arm_group_label>
    <other_name>TSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Patients with gallbladder and cholangiocarcinoma diagnosed by histology or cytology

          3. Liver function Child-Pugh grade A (5-6 points) or better grade B (≤ 7 points)

          4. ECOG score 0 or 1 point

          5. At least one measurable lesion

          6. no previous treatment

        Exclusion Criteria:

          1. organs failure ,including liver ,heart ,kidney

          2. Have received a liver transplant in the past

          3. Active brain metastasis or spinal cord compression

          4. ECOG score 3 or 4 point

          5. Symptomatic peripheral neuropathy (CTCAE ≥ 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guanghai Dai</last_name>
      <phone>13801232381</phone>
      <email>daigh60@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>niansong qian</last_name>
      <phone>18201166535</phone>
      <email>18701317301@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guanghai Dai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Dai, Guanghai</investigator_full_name>
    <investigator_title>professor,deputy cheif of oncology department</investigator_title>
  </responsible_party>
  <keyword>advanced biliary tract cancer</keyword>
  <keyword>Albumin Paclitaxel</keyword>
  <keyword>s1</keyword>
  <keyword>Toripalimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

